Literature DB >> 26363916

MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.

Martin Kolditz1, Hans-Jürgen Seyfarth2, Heinrike Wilkens3, Ralf Ewert4, Tom Bollmann4, Christiane Dinter5, Sabine Hertel5, Hans Klose6, Christian Opitz7, Ekkehard Grünig8, Gert Höffken9, Michael Halank9.   

Abstract

PURPOSE: Besides the established biomarker NT-proBNP, the new cardiovascular biomarkers MR-proANP, MR-proADM, Copeptin, and CT-proET-1 are promising to evaluate hemodynamics, exercise parameters, and prognosis in patients with pulmonary hypertension (PH).
METHODS: 125 consecutive patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were prospectively enrolled at five German PH centers. Blood samples were taken during right heart catheterization. The primary study endpoint was the correlation between biomarkers and hemodynamic and exercise parameters. As secondary endpoint, prediction of 1-year mortality was evaluated.
RESULTS: MR-proADM showed the strongest correlations with 6MWD and VO2peak, whereas NT-proBNP showed the strongest correlations with PVR, PAPm, and CI. In multivariate analysis, only MR-proADM was independently associated with exercise variables, whereas only NT-proBNP independently predicted hemodynamic parameters. All biomarkers were associated with 1-year survival, with MR-proADM showing the highest C index of 0.78. In multivariate analysis, MR-proADM predicted survival independent of age, 6-MWD, CI, RAP, and NT-proBNP. The cut-off of 1.08 nmol/l provided a sensitivity of 83 % and specificity of 66 %.
CONCLUSIONS: Different biomarkers reflect distinctive disease aspects in PH. NT-proBNP best predicts hemodynamic impairment while MR-proADM strongly correlates with exercise capacity. Additionally, MR-proADM represents a promising new marker to evaluate prognosis in patients with PAH and CTEPH. Multi-marker strategies should further be evaluated.

Entities:  

Keywords:  Biomarker; Exercise capacity; Prognosis; Pulmonary hypertension

Mesh:

Substances:

Year:  2015        PMID: 26363916     DOI: 10.1007/s00408-015-9802-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  47 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension.

Authors:  Gaël Deboeck; Cristina Scoditti; Sandrine Huez; Jean-Luc Vachiéry; Michel Lamotte; Linda Sharples; Christian Melot; Robert Naeije
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

3.  Regulation by hypoxia of adrenomedullin output and expression in human trophoblast cells.

Authors:  Emanuela Marinoni; Katia Pacioni; Alessandra Sambuchini; Massimo Moscarini; Claudio Letizia; Romolo DI Iorio
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-11-20       Impact factor: 2.435

4.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

Authors:  C Rubens; R Ewert; M Halank; R Wensel; H D Orzechowski; H P Schultheiss; G Hoeffken
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

5.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

6.  Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index.

Authors:  Daiana Stolz; Kostantinos Kostikas; Francesco Blasi; Wim Boersma; Branislava Milenkovic; Alicia Lacoma; Renaud Louis; Joachim G Aerts; Tobias Welte; Antoni Torres; Gernot G U Rohde; Lucas Boeck; Janko Rakic; Andreas Scherr; Sabine Hertel; Sven Giersdorf; Michael Tamm
Journal:  Eur Respir J       Date:  2013-06-21       Impact factor: 16.671

7.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.

Authors:  F D R Hobbs; R C Davis; A K Roalfe; R Hare; M K Davies; J E Kenkre
Journal:  BMJ       Date:  2002-06-22

8.  Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

Authors:  Roland Wensel; Christian F Opitz; Stefan D Anker; Jörg Winkler; Gert Höffken; Franz X Kleber; Rakesh Sharma; Manfred Hummel; Roland Hetzer; Ralf Ewert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

9.  Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension.

Authors:  Nils P Nickel; Ralf Lichtinghagen; Heiko Golpon; Karen M Olsson; Korbinian Brand; Tobias Welte; Marius M Hoeper
Journal:  Respir Res       Date:  2013-11-19

10.  Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.

Authors:  Werner C Albrich; Kristina Rüegger; Frank Dusemund; Philipp Schuetz; Birsen Arici; Alexander Litke; Claudine A Blum; Rita Bossart; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Petra Schäfer; Maria Schubert; Sabina de Geest; Barbara Reutlinger; Sarosh Irani; Ulrich Bürgi; Andreas Huber; Beat Müller
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

View more
  8 in total

1.  Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.

Authors:  Habib Bouzina; Göran Rådegran
Journal:  Pulm Circ       Date:  2020-06-15       Impact factor: 3.017

2.  MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Authors:  Önsel Öner; Figen Deveci; Selda Telo; Mutlu Kuluöztürk; Mehmet Balin
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

Review 3.  Novel biomarkers for pulmonary arterial hypertension.

Authors:  Anjum Anwar; Gregoire Ruffenach; Aman Mahajan; Mansoureh Eghbali; Soban Umar
Journal:  Respir Res       Date:  2016-07-20

Review 4.  Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.

Authors:  Vanessa Rameh; Antoine Kossaify
Journal:  Biomark Insights       Date:  2016-06-23

5.  Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.

Authors:  Bing Han; Qingli Wang
Journal:  Exp Ther Med       Date:  2018-06-13       Impact factor: 2.447

Review 6.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

7.  Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH.

Authors:  Steffen D Kriechbaum; Lillith Scherwitz; Christoph B Wiedenroth; Felix Rudolph; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Stavros V Konstantinides; Mareike Lankeit; Christoph Liebetrau
Journal:  ERJ Open Res       Date:  2020-11-02

8.  Associations of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BRCA1/2 Mutation Carriers.

Authors:  Jacqueline Lammert; Maryam Basrai; Joachim Struck; Oliver Hartmann; Christoph Engel; Stephan C Bischoff; Anika Berling-Ernst; Martin Halle; Marion Kiechle; Sabine Grill
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-06-03       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.